Piotr Rozentryt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6692213/publications.pdf

Version: 2024-02-01

63 2,847 19 53 g-index

66 66 66 4173

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 2010, 31, 1872-1880.	2.2	515
2	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	2.8	397
3	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, 899-906.	1.7	227
4	The obesity paradox in acute coronary syndrome: a meta-analysis. European Journal of Epidemiology, 2014, 29, 801-812.	5.7	186
5	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1973-1980.	2.8	139
6	The effects of a highâ€caloric proteinâ€rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, doubleâ€blind pilot study. Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 35-42.	7. 3	135
7	Midâ€regional proâ€adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. European Journal of Heart Failure, 2010, 12, 484-491.	7.1	117
8	Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1892.	7.4	88
9	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Coâ€morbidities Aggravating Heart Failure (SICAâ€HF). Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 187-194.	7.3	75
10	The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662.	7.1	59
11	Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122.	7.1	54
12	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 2021, 23, 919-932.	7.1	46
13	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology, 2017, 243, 360-366.	1.7	42
14	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. PLoS ONE, 2011, 6, e14506.	2.5	34
15	Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-13.	4.0	28
16	Remote Supervision to Decrease Hospitalization Rate (RESULT) study in patients with implanted cardioverter-defibrillator. Europace, 2020, 22, 769-776.	1.7	26
17	Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation. Clinical Respiratory Journal, 2018, 12, 930-938.	1.6	23
18	Albumin-to-globulin ratio as an independent predictor of mortality in chronic heart failure. Biomarkers in Medicine, 2018, 12, 749-757.	1.4	23

#	Article	IF	CITATIONS
19	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. European Journal of Preventive Cardiology, 2018, 25, 960-969.	1.8	20
20	Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	4.0	20
21	Acute Coronary Syndromes in Patients with Chronic Kidney Disease. Current Vascular Pharmacology, 2013, 11, 758-767.	1.7	18
22	Weight loss in heart failure is associated with increased mortality only in nonâ€obese patients without diabetes. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1307-1315.	7.3	17
23	Retrospective cross-validation of simplified predictive index for renal replacement therapy after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery, 2008, 7, 1101-1106.	1.1	15
24	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 325-334.	7.3	15
25	Renal function on admission affects both treatment strategy and long-term outcomes of patients with myocardial infarction (from the Polish Registry of Acute Coronary Syndromes). Kardiologia Polska, 2017, 75, 332-343.	0.6	14
26	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686.	7.1	11
27	Comparison of modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas in predicting long-term outcomes in patients undergoing stent implantation due to stable coronary artery disease. Clinical Research in Cardiology, 2014, 103, 569-576.	3.3	10
28	Secular trends in first-time hospitalization for heart failure with following one-year readmission and mortality rates in the 3.8 million adult population of Silesia, Poland between 2010 and 2016. The SILCARD database. International Journal of Cardiology, 2018, 271, 146-151.	1.7	10
29	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. International Journal of Cardiology, 2016, 219, 84-91.	1.7	9
30	Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-14.	4.0	9
31	Accurate Noninvasive Assessment of Myocardial Iron Load in Advanced Heart Failure Patients. Disease Markers, 2020, 2020, 1-7.	1.3	8
32	Pericardial tamponade as a complication of invasive cardiac procedures: a review of the literature. Postepy W Kardiologii Interwencyjnej, 2019, 15, 394-403.	0.2	7
33	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. International Journal of Cardiology, 2014, 177, 248-254.	1.7	6
34	<scp>RE</scp> mote <scp>SU</scp> pervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the <scp>RESULT</scp> study. Annals of Noninvasive Electrocardiology, 2017, 22, .	1,1	6
35	Prevalence, characteristics, and prognostic implications of type 2 diabetes in patients with myocardial infarction: the Polish Registry of Acute Coronary Syndromes (PLâ€'ACS) annual 2018 report. Kardiologia Polska, 2020, 78, 243-246.	0.6	6
36	COnteMporary Modalities In Treatment of Heart Failure: a report from the COMMIT-HF registry. Kardiologia Polska, 2016, 74, 523-528.	0.6	6

#	Article	IF	CITATIONS
37	Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiologia Polska, 2019, 77, 994-999.	0.6	5
38	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiologia Polska, 2021, 79, 363-370.	0.6	4
39	The patient with heart failure in the face of the coronavirus disease 2019 pandemic: an expert opinion of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2020, 78, 618-631.	0.6	4
40	Trends in heart failure mortality in Poland between 1980 and 2010. Polish Archives of Internal Medicine, 2013, 123, 664-671.	0.4	4
41	Prognostic value of novel biomarkers compared with detailed biochemical evaluation in patients with heart failure. Polish Archives of Internal Medicine, 2015, 125, 434-442.	0.4	4
42	Managed Care after Acute Myocardial Infarction (MC-AMI) improves prognosis in AMI survivors with pre-existing heart failure: A propensity score matching analysis of Polish nationwide program of comprehensive post-MI care. Kardiologia Polska, 2022, 80, 293-301.	0.6	4
43	Ceruloplasmin as Redox Marker Related to Heart Failure Severity. International Journal of Molecular Sciences, 2021, 22, 10074.	4.1	3
44	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. Polish Archives of Internal Medicine, 2015, 125, 54-64.	0.4	3
45	Five-year survival of patients with chronic systolic heart failure of ischemic and non-ischemic etiology: analysis of prognostic factors. Kardiochirurgia I Torakochirurgia Polska, 2014, 1, 56-62.	0.1	2
46	Wearable Sensor Vest Design Study for Vital Parameters Measurement System. Advances in Intelligent Systems and Computing, 2017, , 330-337.	0.6	2
47	Nutritional and Non-Nutritional Predictors of Low Spot Urinary Creatinine Concentration in Patients with Heart Failure. Nutrients, 2021, 13, 3994.	4.1	2
48	Heart failure management in Polish medical centers during the coronavirus disease 2019 pandemic: results of a survey. Kardiologia Polska, 2020, 78, 1035-1038.	0.6	2
49	Not All Fat Is Equal. Journal of the American College of Cardiology, 2013, 61, 596-597.	2.8	1
50	Clinical and laboratory determinants of 25-hydroxyvitamin D deficiency during pharmacotherapeutic escalation in heart failure patients. Kardiochirurgia I Torakochirurgia Polska, 2015, 3, 216-227.	0.1	1
51	The role of echocardiographic parameters in predicting survival of patients with lung diseases referred for lung transplantation. Clinical Respiratory Journal, 2019, 13, 212-221.	1.6	1
52	Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients. Journal of Clinical Medicine, 2020, 9, 137.	2.4	1
53	Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology. Advances in Clinical and Experimental Medicine, 2022, 31, 0-0.	1.4	1
54	Siarkowodór — od kÅ,opotliwego zapachu do podrÄ™cznika farmakologii. , 2021, 17, 225-235.	0.1	0

#	Article	IF	CITATIONS
55	Long term outcome of heart failure patients disqualified from heart transplantation. Acta Cardiologica, 2021, 76, 525-533.	0.9	0
56	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 286-293.	0.6	0
57	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 33-41.	0.6	O
58	2017 Monitoring and Teletransmission of Medical-Data in Heart Failure. First Report. Advances in Intelligent Systems and Computing, 2018, , 117-124.	0.6	0
59	Intravenous torasemide for treatment of acute heart failure $\hat{a} \in \text{``practice in Zabrze. Case report.}$ Medycyna Fakt \tilde{A}^3 w, 2019, 12, 186-195.	0.0	O
60	Trajectory of the circulating endothelial progenitor cell levels and their association with acute rejection after heart transplantation. Polish Archives of Internal Medicine, 2019, 129, 889-897.	0.4	0
61	Clinical characteristics and treatment profiles of patients after acute myocardial infarction with left ventricular ejection fraction below 40%: a short 2018–2019 report on the PL‑ACS registry. Kardiologia Polska, 2020, 78, 766-769.	0.6	0
62	Improved prognosis in patients with recurrent hospitalizations for heart failure after day-care management. Kardiologia Polska, 2019, 77, 975-977.	0.6	0
63	The Impact of Short-Term Outdoor Air Pollution on Clinical Status and Prognosis of Hospitalized Patients with Coronary Artery Disease Treated with Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 484.	2.4	O